Facioscapulohumeral Muscular Dystrophy

Losmapimod (GSK-AHAB; GW856553X) is an orally active p38α/β MAPK inhibitor, with pK_i values of 8.1 and 7.6 for p38α and p38β, respectively. Losmapimod reduces DUX4 expression, thus exerting efficacy in facioscapulohumeral muscular dystrophy. By inhibiting MAPK/NF-κB, Losmapimod reduces apoptosis of epileptiform hippocampal neurons, and exhibits anti-allodynia and anti-hyperalgesic activities. Losmapimod blocks the entry and fusion of Lassa fever virus (LASV). Losmapimod overcomes tyrosine kinase inhibitor resistance in non-small cell lung cancer (NSCLC). Losmapimod inhibits myocardial senescence and inflammation, and possesses cardioprotective activity against cardiotoxicity.

Braxlosiran is a component of the AOC reagent Delpacibart braxlosiran (HY-177566), consisting of an siRNA targeting DUX4 (double homeobox protein) and SMCC linker (HY-42360). Delpacibart braxlosiran binds to TfR1. Aberrant expression of the DUX4 protein causes changes in gene expression in muscle cells, which are associated with muscle function loss in facioscapulohumeral muscular dystrophy (FSHD).

FAM labled Braxlosiranis a FAM labled Braxlosiran.

Cy3 labled Braxlosiran is a Cy3 labled Braxlosiran.

Braxlosiran scrambled negative control is the sequence scrambled negative control of Braxlosiran.

Losmapimod (GSK-AHAB; GW856553X) hydrochloride is an orally active p38α/β MAPK inhibitor, with pK_i values of 8.1 and 7.6 for p38α and p38β, respectively. Losmapimod hydrochloride reduces DUX4 expression, thus exerting efficacy in facioscapulohumeral muscular dystrophy. By inhibiting MAPK/NF-κB, Losmapimod hydrochloride reduces apoptosis of epileptiform hippocampal neurons, and exhibits anti-allodynia and anti-hyperalgesic activities. Losmapimod hydrochloride blocks the entry and fusion of Lassa fever virus (LASV). Losmapimod hydrochloride overcomes tyrosine kinase inhibitor resistance in non-small cell lung cancer (NSCLC). Losmapimod hydrochloride inhibits myocardial senescence and inflammation, and possesses cardioprotective activity against cardiotoxicity.

Pinzodirsen (Compound ENTR-Oligo-0034) is a dystrophia myotonica protein kinase (DMPK) steric blocker. Pinzodirsen reduces the nuclear sequestration of toxic DMPK mRNA with splicing factors such as MBNL1 via steric blocking/relocation, or interferes with the secondary structure of CUG repeat RNA, instead of being cleaved by RNase H, thereby ameliorating systemic aberrant splicing in DM1. Pinzodirsen is applicable to the research of myotonic dystrophy.

Losmapimod (GSK-AHAB; GW856553X) (Standard) is the analytical standard of Losmapimod (HY-10402). This product is intended for research and analytical applications. Losmapimod (GSK-AHAB; GW856553X) is an orally active p38α/β MAPK inhibitor, with pK_i values of 8.1 and 7.6 for p38α and p38β, respectively. Losmapimod reduces DUX4 expression, thus exerting efficacy in facioscapulohumeral muscular dystrophy. By inhibiting MAPK/NF-κB, Losmapimod reduces apoptosis of epileptiform hippocampal neurons, and exhibits anti-allodynia and anti-hyperalgesic activities. Losmapimod blocks the entry and fusion of Lassa fever virus (LASV). Losmapimod overcomes tyrosine kinase inhibitor resistance in non-small cell lung cancer (NSCLC). Losmapimod inhibits myocardial senescence and inflammation, and possesses cardioprotective activity against cardiotoxicity.